DB18186InvestigationalGene Therapies
BMN-351 is a fully modified 18-mer oligonucleotide with a TEG modification at its 5' end that binds to exon 51 of dystrophin pre-mRNA. It is under investigation for the treatment...
- Code names
- BMN-351
What you can answer from here — as of February 07, 2026
Which companies are running trials of BMN-351, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account